For citations:
Alyautdin R.N., Romanov B.K., Pereverzev A.P., Chikalo A.O., Bunyatyan N.D., Merkulov V.A., Mironov A.N. Alipogene tiparvovec: a long journey of risk-benefit ratio assessment of gene therapy products. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. 2015;(1):31-34. (In Russ.)
Email this article 